We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Peptide from Umbilical Cord Blood Shuts Down a Neutrophil Inflammatory Factor

By LabMedica International staff writers
Posted on 19 Sep 2016
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Image: Infection fighting cells from umbilical cord blood (left) and circulating blood three days after birth (right) from the same prematurely born baby. Umbilical cord blood has high levels of neonatal NET inhibitory factor (nNIF), which inhibits formation of neutrophil extracellular traps (NETs) (Photo courtesy of Mark Cody/Diana Lim, University of Utah Health Care).
Researchers have isolated a peptide in umbilical cord blood that blocks the formation of neutrophil extracellular traps (NETs) and reduces inflammation and risk of developing sepsis.

NETs are molecular lattices of decondensed chromatin embedded with histones, granule enzymes, and antimicrobial peptides that are extruded by immune system neutrophil granulocytes, (polymorphonuclear leukocytes or PMNs) to capture and contain bacteria, viruses, and other pathogens. Experimental evidence has indicated that NETs also cause inflammatory vascular and tissue damage, suggesting that identifying pathways that inhibit NET formation may have therapeutic implications.

After examining various potential sites for the presence of a NET inhibitor, investigators at University of Utah Health Care (Salt Lake City, USA) discovered a peptide in umbilical cord blood that inhibited NET formation in vitro and in vivo and that appeared to be an endogenous regulator of NET generation.

They reported in the September 6, 2016, online edition of The Journal of Clinical Investigation that in addition to this neonatal NET-inhibitory factor (nNIF), they had also identified additional nNIF-related peptides (NRPs) that inhibited NET formation. These nNIFs and NRPs blocked NET formation induced by pathogens, microbial toxins, and pharmacologic agonists in vitro and in mouse models of infection and systemic inflammation, and they improved mortality in mouse models of systemic inflammation.

"We found something we were not expecting, and it has taken us to new strategies for therapy that did not exist before," said senior author Dr. Guy Zimmerman, professor of internal medicine at University of Utah Health Care.

Related Links:
University of Utah Health Care

Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Immunofluorescence Analyzer
IFA System

Channels

Clinical Chemistry

view channel
Image: A simple oral swab detected blood-matched inflammatory signals in children with primary ciliary dyskinesia, offering a needle-free way to monitor inflammation during routine care (Image credit: Shutterstock)

Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia

Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
ADLM